Abeona Therapeutics

Abeona Therapeutics (NASDAQ: ABEO) is an early-stage biotechnology company focused on developing therapies for the deadly childhood genetic diseases Sanfilippo (SF) Syndrome Type A and Type B. Our two lead products, ABX-A and ABX-B, uniquely deliver the therapeutic product to the central nervous system with the aim of reversing the effects of the genetic errors that cause the disease. We are currently seeking funds for a Series A financing to complete two Phase I/II clinical trials.
Read the Case Study

News: Abeona Granted Licenses to Develop Gene Therapies for Four Rare Disorders